This is a U.S. news story, published by CNBC, that relates primarily to Kevin Sayer news.
For more U.S. news, you can click here:
more U.S. newsFor more Kevin Sayer news, you can click here:
more Kevin Sayer newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Dexcom shares. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Dexom news, Earnings news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
DexcomCNBC
•
87% Informative
Dexcom shares fell on Thursday after the company released third-quarter results that beat expectations but showed slow revenue growth.
The company's revenue increased 2% from $975 million a year earlier , but its U.S. revenue declined 2% .
CEO Kevin Sayer attributed challenges to a restructuring of the company's sales team, fewer new customers than expected and lower revenue per user.
VR Score
93
Informative language
94
Neutral language
86
Article tone
formal
Language
English
Language complexity
39
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
2
Source diversity
1
Affiliate links
no affiliate links